Ironwood to look for alternative paths after FDA asks for another Phase 3
Ironwood Pharmaceuticals is now working with Goldman Sachs in its hunt for company alternatives after getting regulatory feedback from the FDA.
The Boston drugmaker hoped …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
